jtt 501 has been researched along with phosphotyrosine in 1 studies
| Studies (jtt 501) | Trials (jtt 501) | Recent Studies (post-2010) (jtt 501) | Studies (phosphotyrosine) | Trials (phosphotyrosine) | Recent Studies (post-2010) (phosphotyrosine) |
|---|---|---|---|---|---|
| 21 | 0 | 1 | 6,475 | 4 | 751 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, T; Haneda, M; Hidaka, H; Kashiwagi, A; Kikkawa, R; Kojima, H; Maegawa, H; Morino, K; Nishio, Y; Obata, T; Shibata, T; Ugi, S; Yasuda, H | 1 |
1 other study(ies) available for jtt 501 and phosphotyrosine
| Article | Year |
|---|---|
A new antidiabetic agent (JTT-501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle.
Topics: Animals; Blood Glucose; Drug Synergism; Glucose; Glucose Clamp Technique; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Immunosorbent Techniques; Insulin; Isoxazoles; Male; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Phosphotyrosine; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptor, Insulin; Signal Transduction | 1999 |